Igen Biolab Group
  • Home
  • About us
  • Pipeline
  • Tecnology
  • Press
    • News
    • Press Releases
    • Events
    • Publications
  • Contact
  • English
    • Español
Select Page
Unhealthy Gut Helps Breast Cancer Spread, Research Reveals

Unhealthy Gut Helps Breast Cancer Spread, Research Reveals

by Igen BioLab Group | Dec 7, 2022 | Events, News

An unhealthy gut triggers changes in normal breast tissue that helps breast cancer spread to other parts of the body, new research from UVA Cancer Center reveals. The gut microbiome – the collection of microbes that naturally live inside us – can be disrupted by poor...
Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis

Chronic liver disease enables gut Enterococcus faecalis colonization to promote liver carcinogenesis

by Igen BioLab Group | Nov 22, 2021 | Publications

Gut dysbiosis is observed in chronic hepatobiliary diseases and is frequently associated with liver carcinogenesis; however, the extent and specific mechanisms triggered by alterations in the microbiota mediating tumorigenesis in these patients remain unclear. Here we...
Gut Bacteria may Fuel prostate Cancer Treatment Resistance

Gut Bacteria may Fuel prostate Cancer Treatment Resistance

by Igen BioLab Group | Oct 25, 2021 | Publications

A mainstay of treatment for prostate cancer is to deprive it of androgens, the hormones that make it grow. The testes are the main source of these hormones, so treatment can consist of either surgical removal of these organs or use of drugs to block...
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme

Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme

by Igen BioLab Group | Sep 1, 2020 | Publications

The dose-limiting side effect of the common colon cancer chemotherapeutic CPT-11 is severe diarrhea caused by symbiotic bacterial β-glucuronidases that reactivate the drug in the gut. We sought to target these enzymes without killing the commensal bacteria essential...

Recent Posts

  • Gut Microbiota Modulation of Efficacy and Toxicity of Cancer Chemotherapy and Immunotherapy
  • Distinct respiratory microbiota associates with lung cancer clinicopathological characteristics
  • MD Anderson and Federation Bio announce collaboration to develop novel microbiome treatment for patients with immunotherapy-resistant cancers
  • Intratumor microbiota: a novel tumor component
  • Microbiota and Cancer: The Emerging Beneficial Role of Bifidobacteria in Cancer Immunotherapy
  • LEGAL NOTICE
  • PRIVACY AND DATA PROTECTION
  • Cookie policy
  • Facebook
  • Twitter
  • Instagram
  • RSS
Design by loComunicas

This website uses its own and third-party cookies in order to analyze the traffic generated for statistical purposes.

You can accept all cookies by clicking "Accept", reject all of them by clicking "Deny" or configure them by clicking "Settings".

For more information on how this site uses cookies and related technologies, you can read our Policy on Cookies

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly necessary cookies

Strictly necessary cookies must always be activated so that we can save your cookie settings preferences.

If you deactivate this cookie, we will not be able to save your preferences. This means that every time you visit this website you will have to activate or deactivate cookies again.

Third party cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, or the most popular pages.

Leaving this cookie active allows us to improve our website.

Please activate the strictly necessary cookies first so that we can save your preferences!

Cookies policy

More information about our cookie policy